Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Follow-Up Questions
Qui est le CEO de Acrivon Therapeutics Inc ?
Dr. Peter Blume-Jensen est le Chairman of the Board de Acrivon Therapeutics Inc, il a rejoint l'entreprise depuis 2018.
Quelle est la performance du prix de l'action ACRV ?
Le prix actuel de ACRV est de $2.14, il a decreased de 0.41% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Acrivon Therapeutics Inc ?
Acrivon Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Acrivon Therapeutics Inc ?
La capitalisation boursière actuelle de Acrivon Therapeutics Inc est de $67.3M
Est-ce que Acrivon Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Acrivon Therapeutics Inc, y compris 4 achat fort, 9 achat, 2 maintien, 0 vente et 4 vente forte
